Lit Matters #3 - MENDS2 - Propofol vs Dexmedetomidine

In mechanically ventilated adults with sepsis, dexmedetomidine did not outperform propofol on delirium-free days, ventilator-free days, or 90-day mortality. The practical signal for ICU sedation is that either agent is reasonable when light sedation is the target and opioids are doing much of the work.

Sepsis Vent Sedation Trial

• Neutral primary outcomes: Delirium- and coma-free days were essentially identical at about 10.7 versus 10.8 days, reinforcing that dexmedetomidine was not clinically superior to propofol in this sepsis cohort.
• No ventilator benefit: Ventilator-free days were also the same at roughly 24 days, arguing against a meaningful liberation advantage for dexmedetomidine in mechanically ventilated septic adults.
• Similar mortality signal: Ninety-day mortality was nearly superimposable at 38% versus 39%, making any survival advantage unlikely and leaving sedative choice largely a matter of context and preference.
• Light sedation target: Both groups spent only about 60% of time at the intended RASS target, a reminder that protocolized sedation often underdelivers even in a blinded ICU trial. We get into why that matters in the episode.
• Tiny study drug doses: Median doses were strikingly low at 0.27 mcg/kg/hr for dexmedetomidine and about 10 mcg/kg/min for propofol, which limits broad claims about either drug at more aggressive dosing.
• Opioid-heavy rescue strategy: Fentanyl was the main rescue agent rather than another sedative, with median rates around 60 mcg/hr, suggesting the comparison was really sedative choice layered onto substantial opioid exposure.